Sanofi stops supply of high cholesterol drug to China due to limited availability
SHANGHAI (Reuters) -Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French pharmaceuticals firm and its partner Regeneron Pharmaceuticals, in China due to limited availability. “The surge in demand has led to limited availability in China, and some other countries,” Sanofi said in a statement sent to …
Sanofi stops supply of high cholesterol drug to China due to limited availability Read More »







